PDSB MEXC RealStocks
Own real PDSB shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 14:16:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PDS Biotechnology Corporation (PDSB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.98, with a market capitalization of $71.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.20 to $1.79. This page covers its latest market performance, valuation, price trends and company information.
$71.02M | |
$0.97 | |
$1.03 | |
$0.96 | |
$0.98 | |
58.31K | |
25.81M | |
-- | |
$1.79 | |
$0.20 | |
-- | |
-- |
PDS Biotechnology Corporation (PDSB) is trading at $0.98 in pre-market trading as of 2026-11-13 14:15:00, down 0.41% ($0.00) from the previous close of $0.98
Pre-market trading shows how investors are pricing PDSB before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, PDS Biotechnology Corporation (PDSB) moved from $1.17 to $0.98, representing a decline of 16.58% ($0.19).
The stock traded between $0.92 and $1.29 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.97 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 49.0%
PDSB is currently trading at $0.98, placing it 49.0% of the way from its 52-week low of $0.20 to its 52-week high of $1.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PDS Biotechnology Corporation (PDSB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PDSB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PDSB shares and USD.
PDSB Shares to USD
1.00 PDSB shares = 0.976 USD
Calculations are estimates based on the latest available price and are for reference only.